Approval · Notice of Compliance 12470 · 2011
TEVA-SUMATRIPTAN: Notice of Compliance 12470
Issued June 28, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12470
- Date
- June 28, 2011
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- 5-HT1 Receptor agonist / Migraine therapy
- Canadian reference product
- IMITREX / IMITREX DF (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-SUMATRIPTAN | 02239367 | Marketed |
| TEVA-SUMATRIPTAN DF | 02286815 | Marketed |
| TEVA-SUMATRIPTAN DF | 02286823 | Marketed |
| TEVA-SUMATRIPTAN DF | 02286831 | Marketed |
| SUMATRIPTAN INJECTION | 02330571 | Cancelled Pre Market |
Medicinal ingredients
- SUMATRIPTAN 100 MG per TAB
- SUMATRIPTAN 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 12 MG per ML